LOX-1, OxLDL, and atherosclerosis

QR Code

LOX-1, OxLDL, and atherosclerosis

Oxidized low-density lipoprotein (OxLDL) contributes to the atherosclerotic plaque formation and progression by several mechanisms, including the induction of endothelial cell activation and dysfunction, macrophage foam cell formation, and smooth muscle cell migration and proliferation. Vascular wal...

Full description

Bibliographic Details
Main Authors:	Pirillo, A., Norata, Giuseppe, Catapano, A.
Format:	Journal Article
Published:	Hindawi Publishing Corporation 2013
Online Access:	http://hdl.handle.net/20.500.11937/55563

Similar Items

Cryptotanshinone attenuates in vitro oxLDL-induced pre-lesional atherosclerotic events.
by: Ang, Kok Pian, et al.
Published: (2011)

HDLs, immunity, and atherosclerosis
by: Norata, Giuseppe, et al.
Published: (2011)

Oxidant Production, oxLDL uptake and CD36 levels in Human Monocyte Derived Macrophages are down regulated by the macrophage - generated antioxidant 7,8-dihydroneopterin
by: Gieseg, S.P, et al.
Published: (2010)

The Interplay of Lipids, Lipoproteins, and Immunity in Atherosclerosis
by: Pirillo, A., et al.
Published: (2018)

The CD1d-natural killer T cell axis in atherosclerosis
by: Bondarenko, S., et al.
Published: (2014)

Statins and periodontal inflammation: A pleiotropic effect of statins or a pleiotropic effect of LDL-cholesterol lowering?
by: Norata, Giuseppe, et al.
Published: (2014)

New therapeutic principles in dyslipidaemia: Focus on LDL and Lp(a) lowering drugs
by: Norata, Giuseppe, et al.
Published: (2013)

Leonurine: A new comer in the natural compounds affecting atherosclerosis
by: Norata, Giuseppe, et al.
Published: (2012)

High density lipoproteins and atherosclerosis: Emerging aspects
by: Sala, F., et al.
Published: (2012)

Niemann-pick C1-like 1 (NPC1L1) inhibition and cardiovascular diseases
by: Pirillo, A., et al.
Published: (2016)

LOX-1 inhibition in ApoE KO mice using a schizophyllan-based antisense oligonucleotide therapy
by: Amati, F., et al.
Published: (2012)

Pentraxins and atherosclerosis
by: Barbati, E., et al.
Published: (2014)

Translating the biology of adipokines in atherosclerosis and cardiovascular diseases: Gaps and open questions
by: Ruscica, M., et al.
Published: (2017)

MicroRNAs and lipoproteins: A connection beyond atherosclerosis?
by: Norata, Giuseppe, et al.
Published: (2013)

High-density lipoprotein subfractions - What the clinicians need to know
by: Pirillo, A., et al.
Published: (2013)

Treating high density lipoprotein cholesterol (HDL-C): Quantity versus quality
by: Pirillo, A., et al.
Published: (2013)

Postprandial lipemia as a cardiometabolic risk factor
by: Pirillo, A., et al.
Published: (2014)

Vascular inflammation and low-density lipoproteins: Is cholesterol the link? A lesson from the clinical trials
by: Catapano, A., et al.
Published: (2017)

Therapy and clinical trials: Aggressive statin therapy versus combined and emerging approaches
by: Catapano, A., et al.
Published: (2011)

HDL in infectious diseases and sepsis
by: Pirillo, A., et al.
Published: (2015)

Targeting Cholesterol in Non-ischemic Heart Failure: A Role for LDLR Gene Therapy?
by: Catapano, A., et al.
Published: (2017)

Strategies for the use of nonstatin therapies
by: Pirillo, A., et al.
Published: (2017)

Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: Patient selection and perspectives
by: Catapano, A., et al.
Published: (2017)

Fibronectin extra domain A stabilises atherosclerotic plaques in apolipoprotein E and in LDL-receptor-deficient mice
by: Pulakazhi Venu, V., et al.
Published: (2015)

Effect of Tie-2 conditional deletion of BDNF on atherosclerosis in the ApoE null mutant mouse
by: Norata, Giuseppe, et al.
Published: (2012)

Chronic Monosodium Methylarsonate (MSMA) exposure induces oxidation of Low Density Lipoprotein (LDL) and early atherosclerosis development
by: Adekunle, Ishola Afeez, et al.
Published: (2015)

Apolipoprotein C-III: From Pathophysiology to Pharmacology
by: Norata, Giuseppe, et al.
Published: (2015)

Effector memory T cells are associated with atherosclerosis in humans and animal models
by: Ammirati, E., et al.
Published: (2012)

Subclinical atherosclerosis is associated with Epicardial Fat Thickness and hepatic steatosis in the general population
by: Baragetti, A., et al.
Published: (2016)

IDOL N342S variant, atherosclerosis progression and cardiovascular disorders in the italian general population
by: Dhyani, A., et al.
Published: (2015)

Emerging role of high density lipoproteins as a player in the immune system
by: Norata, Giuseppe, et al.
Published: (2012)

HDL: To treat or not to treat?
by: Pirillo, A., et al.
Published: (2014)

HDL in innate and adaptive immunity
by: Catapano, A., et al.
Published: (2014)

PCSK9 inhibition in statin-intolerant HeFH patients: What's new?
by: Casula, M., et al.
Published: (2017)

Genetically determined telomeres shortening is associated with carotid atherosclerosis progression and increased incidence of cardiovascular events
by: Baragetti, A., et al.
Published: (2016)

Biology of proprotein convertase subtilisin kexin 9: Beyond low-density lipoprotein cholesterol lowering
by: Norata, Giuseppe, et al.
Published: (2016)

MiR-143/145 deficiency attenuates the progression of atherosclerosis in Ldlr-/- mice
by: Sala, F., et al.
Published: (2014)

Markers of inflammation associated with plaque progression and instability in patients with carotid atherosclerosis
by: Ammirati, E., et al.
Published: (2015)

Antigen-dependent and antigen-independent pathways modulate CD4 +CD28 null T-cells during atherosclerosis
by: Ammirati, E., et al.
Published: (2012)

HDL and adaptive immunity: A tale of lipid rafts
by: Norata, Giuseppe, et al.
Published: (2012)

Cannot write session to /tmp/vufind_sessions/sess_ufdphlj8q6d4okfcp43mda3cg4